Nidolon

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nidolon

Property Description
Active ingredient Nimesulide
Form Tablet, oral suspension, granules, topical gel
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
General purpose Relief of pain, inflammation, and fever
Origin Synthetic sulfonanilide compound

Classification, Origin, and Forms

Nidolon is a synthetic medicinal entity that is typically a prescription-only medicine, with the active ingredient being Nimesulide. It is fundamentally classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Nimesulide is structurally defined as a sulfonanilide derivative, a feature that distinguishes it chemically from traditional NSAID families. Its mechanism is clinically recognized as functioning as a preferential cyclooxygenase-2 (COX-2) inhibitor, meaning it targets the enzyme primarily responsible for the inflammatory response.

Nidolon is a single-ingredient product, centered entirely on Nimesulide. The medicine is presented in forms suitable for both systemic and topical routes of administration. These preparations include the standard oral tablet, dispersible granules for oral suspension—often formulated with an additive to improve patient compliance—and a topical gel for localized relief.

General Purpose and Primary Benefit

The overall general purpose of Nidolon is to serve as a symptomatic agent that provides relief by mitigating the key physical manifestations of inflammation. This includes its capacity for combined analgesia (pain relief), anti-inflammation, and antipyresis (fever reduction). Nimesulide is used for providing symptomatic treatment for acute pain. This reflects the medicine's foundational role in helping to manage and reduce acute physical discomfort linked to an inflammatory event.

Regulatory References

  1. Nimesulide - referral

What side effects are possible with Nidolon?

Possible Side Effects and Safety Information

The official safety information for Nidolon, as documented by government regulatory bodies, outlines specific adverse reactions and safety restrictions that define its risk profile. The safety data is organized by the frequency of reactions observed in clinical trials and by the specific body system affected, known as System-Organ Classes.


Serious Adverse Reactions and Safety Restrictions

Nidolon carries a risk of serious, organ-specific toxicity. Regulatory documents mandate prominent warnings regarding the potential for severe hepatotoxicity (liver damage). This risk has led to significant safety limitations:

  • Restrictions on Use: The drug is typically restricted to use only as a second-line therapy after other treatment options have been exhausted.
  • Duration Limitation: Regulatory documents explicitly restrict the maximum duration of treatment due to the exposure-related risk of serious adverse events.
  • Contraindicated Populations: The use of Nidolon is prohibited in patients with pre-existing hepatic or renal impairment and in women who are pregnant or breastfeeding.

Common Adverse Reactions

Adverse reactions classified as common are based on specific incidence rates (e.g., greater than or equal to 1% incidence and higher than placebo) from controlled studies. These commonly reported events involve several system-organ classes, including gastrointestinal, nervous system, and skin.

Post-Marketing Surveillance

Following regulatory approval, ongoing surveillance identifies Post-Marketing Safety Signals, which are adverse events reported spontaneously. These signals may lead to updates in the official labeling to reflect newly recognized, potentially serious risks or to reinforce the need for specific safety monitoring.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Nidolon (Nimesulide) overdose documents potential presentations that range from being asymptomatic to developing mild, self-limiting effects such as nausea, vomiting, abdominal pain, and drowsiness. Overdose classifications indicate that ingestion of large doses carries a risk of progression to serious systemic outcomes, requiring mandatory medical attention.

The physiological systems documented as being critically affected include the gastrointestinal system, where bleeding and perforation are risks, the renal system (acute failure), and the hepatobiliary system, where severe hepatic injury, including rare cases of fulminant hepatitis, has been reported. Population-specific notes indicate the elderly are at an increased risk of severe adverse reactions, particularly gastrointestinal bleeding, a risk relevant to overdose scenarios.

The mandated emergency action is to seek immediate medical attention for any suspected overdose or if severe symptoms are observed. Regulatory guidance confirms that no specific antidote is known, meaning management is strictly symptomatic and supportive. Procedural measures include considering the administration of activated charcoal within a short timeframe following large ingestion. Hospital monitoring is required for symptomatic patients and large ingestions, often for 4 to 8 hours, with necessary laboratory investigations to monitor renal function, liver function, and acid-base status.

Therapeutic Uses of Nidolon

What Nidolon Treats: Main Uses and Benefits

The primary role of Nidolon (Nimesulide) is to provide symptomatic relief for acute, short-term situations where discomfort, inflammation, and fever create noticeable physiological strain. The medication is commonly used across conditions presenting with acute episodes, including acute pain and primary dysmenorrhea. It is applied across domains where additional symptomatic support is needed, helping to ease the overall symptom burden.

Nidolon is commonly used to help with symptoms related to inflammatory or irritative states and systemic imbalance, such as pain, swelling, and elevated body temperature (fever). Clinical scenarios include managing discomfort after soft tissue injuries like sprains and strains, assisting with pain during painful osteoarthritis flare-ups, and supporting patients during the acute cramping characteristic of menstrual pain. Symptomatic relief helps patients cope more steadily with difficult episodes and supports general well-being during symptomatic phases.


Quick Facts: Therapeutic Domains

  • Acute Pain Management: Relevant when supportive symptom management is appropriate for mild to moderate pain.
  • Inflammatory Symptoms: Applied in scenarios where additional management of discomfort is required due to localized swelling and inflammation.
  • Episodic Discomfort: Used in situations involving recurrent or episodic manifestations, such as primary dysmenorrhea or osteoarthritis flare-ups.

Regulatory References

  1. European Medicines Agency Nimesulide Referral

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Nidolon — official regulatory information

Nidolon (Nimesulide) is subject to strict official eligibility rules that define which populations are permitted to use the medicine.

Classification Eligibility Status
Approved Age Groups Adults and Adolescents (Age 12–18 years).
Treatment Line Restricted to second-line treatment only.
Maximum Duration Restricted to a maximum of 15 days.
Conditional Use Older adults and patients with mild to moderate renal impairment require appropriate clinical monitoring.

Absolute Contraindications

Systemic Nidolon is strictly contraindicated and must not be used in the following populations:

  • Pediatric Exclusion: Children under 12 years of age.
  • Organ Function: Patients with any degree of hepatic impairment or severe renal impairment (creatinine clearance < 30 ml/min).
  • Gastrointestinal: Patients with active gastrointestinal ulceration, bleeding, or perforation.
  • Cardio/Bleeding: Patients with severe heart failure or severe coagulation disorders.
  • Reproductive Status: Women in the third trimester of pregnancy.

Use is not recommended for women in the first and second trimesters of pregnancy, during lactation (breastfeeding), or for those attempting to conceive.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Nidolon (Nimesulide) establishes interactions through pharmacokinetic and pharmacodynamic mechanisms, leading to specific restrictions and cautions.

Contraindicated and Non-Recommended Combinations

The medicine is contraindicated for use with other potentially hepatotoxic substances and in patients with severe coagulation disorders. Co-administration with Anticoagulants (such as Warfarin) and other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) is officially not recommended due to an increased risk of bleeding complications and other adverse effects. Alcohol abuse must also be avoided during treatment due to the heightened risk of hepatic reactions.

Pharmacokinetic and Exposure Effects

Nidolon is documented as an inhibitor of the CYP2C9 enzyme. This pharmacokinetic interaction may cause increased plasma concentrations of drugs metabolized by this enzyme, including Lithium and Methotrexate. For Methotrexate, regulatory documents require caution if administration occurs less than 24 hours before or after Nidolon treatment.

Pharmacodynamic Risk and Population Cautions

Nidolon's pharmacodynamic effects caution against use with agents that influence hemostasis or renal function. Combination with Diuretics, ACE Inhibitors, or Angiotensin II Antagonists may lead to a deterioration of renal function. This specific risk requires particular caution when co-administering these agents in elderly patients.

Mechanism of Action

Preferential Inhibition of the COX-2 Pathway

The molecule primarily acts as a preferential inhibitor of the Cyclooxygenase-2 ( COX-2) enzyme. This enzyme functions in the Arachidonic Acid Cascade, producing inflammatory mediators, chiefly Prostaglandin E2 ( PGE2). By limiting PGE2 production in the periphery and in the hypothalamus, this mechanism influences chemical signals that alter nociceptor sensitivity and modify the hypothalamic thermoregulatory setpoint.


Modulation of Cellular Oxidative Stress

Beyond its principal enzyme target, the mechanism involves modulating the activity of key inflammatory cells. Nimesulide acts by both inhibiting Myeloperoxidase (MPO) and directly scavenging Reactive Oxygen Species (ROS) (free radicals). This multi-modal action limits the release of immune-derived oxidants and degradative enzymes, influencing the structural integrity of the extracellular matrix by reducing the cellular component of oxidative stress.

Dosage and Administration Information

How to Use Nidolon

Nidolon (Nimesulide) is administered according to specific systemic (oral) and localized (topical) use patterns, utilizing the minimum effective dose for the shortest possible duration. Systemic use is restricted to second-line treatment, meaning it is reserved for situations where other initial options are not considered appropriate.


Systemic Oral Administration

The standard adult systemic dose is 100 mg, which should be taken twice daily (morning and evening). This establishes a maximum daily intake of 200 mg. Oral forms, whether tablets or granules (which must be dispersed in water), must be taken after a meal. The total treatment course for systemic use is strictly limited to a maximum duration of 15 days. If a systemic dose is missed, it should be taken as soon as remembered, but doubling the dose to compensate is not permitted.

Topical Use and Restrictions

The topical gel is intended for localized application and is typically applied two or three times daily. The proper administration involves applying a thin layer, approximately 6 cm to 7 cm long, and gently massaging it into the affected area until it is fully absorbed. The gel must not be applied to broken or denuded skin, and the use of occlusive dressings is not permitted.

Population-Specific Usage Rules

Nidolon is contraindicated for use in children under 12 years of age. In the adult population, no dosage adjustment is generally required for older adults or for patients with mild to moderate renal impairment.

Recent Clinical Evidence

Research evidence / Overview of Studies for Nidolon

Evidence for Use in Acute Pain

Research into the management of acute pain using Nimesulide (the active ingredient in Nidolon) has primarily been conducted through numerous short-term Randomized Controlled Trials (RCTs). Studies primarily enrolled adult populations (18 years and older) experiencing mild to moderate pain that was acute. They examined outcomes related to physical discomfort, including evaluating the speed of effect onset and how the overall pain intensity changed over time. Studies reported measurements related to the speed of effect onset and changes in physical discomfort over the defined observation period. Systematic reviews and meta-analyses examined the consistency of findings related to changes in symptoms when compared against placebo and other medicines. The applicability of this research is strictly limited, as trials typically involve observation periods not exceeding 15 days.


Evidence for Use in Primary Dysmenorrhea

Research explored the use of Nimesulide for the management of symptoms related to primary dysmenorrhea (acute menstrual pain). These studies were conducted through short-term RCTs focusing on women and adolescents experiencing symptomatic, acute episodes. Research examined how patient-reported outcomes evolved in the observed populations during the symptomatic phase of the menstrual cycle. Trials reported measurements showing changes in the severity of menstrual pain compared to placebo. The evidence base contributes to understanding symptom patterns for this specific indication. Studies are very short-term, covering only the symptomatic period of one or two cycles.


Research Scope for Osteoarthritis Symptoms

Nimesulide was previously evaluated in research exploring symptomatic patterns associated with painful osteoarthritis (OA) flare-ups. Trials assessed measurements of functional indices and subjective pain scores during short-term observation periods. The existing evidence relates solely to acute, short-duration use, reflecting regulatory limits on treatment duration due to the nature of chronic conditions.


What Research Gaps and Uncertainties Exist

Long-term outcomes are not well characterized in the existing evidence base. The most significant limitation is the official restriction on treatment duration, which means the research provides limited information for long-term outcomes. Data for certain groups, particularly children under 12, older adults, and individuals with defined comorbidities, remain insufficient or were specifically excluded from key efficacy trials. Comparative evidence is lacking to fully assess the medicine's profile against every available alternative pain relief option.

Frequently Asked Questions (FAQ)

Common questions about Nidolon (FAQ)


Q: What is the main difference between Nidolon and similar drugs in the same class?

A: As described in official product information, Nidolon is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID).

Its mechanism is described as being a preferential inhibitor of the COX-2 enzyme. This indicates it primarily targets the enzyme responsible for inflammation, which is a functional distinction compared to traditional NSAIDs that may affect both COX-1 and COX-2.


Q: How quickly does Nidolon start to show an effect?

A: Studies examining how the medicine moves through the body, known as pharmacokinetics, indicate that it begins to reach its highest levels in the bloodstream relatively quickly.

Maximum concentrations are generally achieved within 1.2 to 3.8 hours after taking an oral dose.


Q: How long does the effect of one dose of Nidolon typically last?

A: The pharmacological duration of one dose is related to how quickly the body clears the medicine.

The half-life—the time it takes for half of the dose to be cleared—of the active ingredient typically ranges from 2 to 5 hours. The breakdown product (active metabolite) stays in the body slightly longer, with a half-life of about 3 to 9 hours.


Q: Are there any common foods or supplements that should be avoided while taking Nidolon?

A: Official product information advises strictly avoiding alcohol abuse while using Nidolon, as this combination carries a heightened risk of serious liver reactions.

Outside of alcohol, the official regulatory documents do not specify a general restriction on common foods or routine over-the-counter supplements.


Q: Is Nidolon known to be habit-forming?

A: Based on information from government drug databases, the active ingredient in Nidolon is generally not categorized as a substance that is habit-forming or associated with dependency.


Q: Can people with [broad common condition, e.g., high blood pressure] generally use Nidolon?

A: The official eligibility criteria describe the need for caution in patients who have pre-existing cardiac impairment.

However, the medicine is strictly prohibited (contraindicated) for use in patients who have severe heart failure.


Q: What are the most commonly reported side effects of Nidolon in general patient populations?

A: The most commonly reported adverse reactions observed in clinical trials involve the gastrointestinal system, and these effects can include nausea, vomiting, abdominal pain, and diarrhea.

Nervous system effects such as headache and dizziness are also commonly reported in official safety documentation.


Q: How does the body get rid of Nidolon after it has been taken?

A: According to official data, the medicine is processed primarily through metabolism in the liver.

Approximately 50% of the total dose is eliminated from the body through the urine. The remaining portion, about 29%, is excreted via the faeces.


Q: Can older adults typically use Nidolon without special precautions?

A: For older adults, official documents state that a change in the standard dose is generally not required.

However, caution is advised for this population, particularly when using the medicine alongside other drugs, such as diuretics, that may influence kidney function.


Q: Do studies suggest that Nidolon affects sleep patterns?

A: The official safety profile includes somnolence, which is a medical term for drowsiness or sleepiness, as a possible reported adverse reaction.

Somnolence is an effect that may be reported, and it can influence alertness.


Q: Can someone drive or operate machinery while taking Nidolon?

A: Regulatory guidance specifically addresses the ability to drive or operate machinery due to the potential for side effects like dizziness or visual disturbances.

Official guidance suggests caution regarding these activities until an individual is aware of how the medicine may affect their coordination or mental state.


Q: Is there any difference in how Nidolon works for men versus women?

A: Studies that track how the body handles the medicine show that there is only a limited difference between men and women regarding how Nidolon is processed and eliminated.

Therefore, gender is not typically considered a primary factor impacting the medicine's overall action in the body.


Q: Does taking Nidolon require regular blood tests or monitoring?

A: Official documents emphasize that Nidolon is restricted to a short duration of use due to the risk of severe liver effects.

If a medical decision is made to use the medicine for longer than the specified period, some regulatory guidance describes the need for liver function tests to be assessed periodically for monitoring purposes.


Q: Can Nidolon be taken with a specific type of food (e.g., grapefruit juice)?

A: The administration instructions emphasize that the oral dose should be taken after a meal to help reduce potential gastrointestinal issues.

While the medicine does interact with certain other drugs, official drug interaction summaries do not specifically list grapefruit or grapefruit juice as a restricted product.


Q: Are there specific symptoms that require immediate medical attention while on Nidolon?

A: Official warnings describe specific symptoms that warrant attention and may signal a serious reaction.

These include unexplained nausea, vomiting, dark urine, fatigue, abdominal pain, or jaundice (a yellowing of the skin or eyes), and warrant prompt medical attention.


Q: Is there any official guidance on taking Nidolon with herbal supplements?

A: Official regulatory guidance describes the importance of informing a healthcare provider of all products being taken, including supplements and herbal products.

This practice helps manage the risk of potential interactions.


Q: Is it necessary to take Nidolon at the exact same time every day?

A: The official administration instructions require taking the dose twice daily, usually in the morning and evening.

Maintaining a consistent time is generally noted as helpful for achieving stable levels of the medicine in the body.


Q: Does Nidolon interact with common vitamins?

A: Official drug interaction summaries are focused on identifying clinically significant interactions, primarily between different medicines or with pre-existing diseases.

These summaries do not typically include restrictions regarding common, daily vitamins.


Q: Does Nidolon have a 'Black Box Warning'?

A: The medicine is subject to very strict safety restrictions and warnings from regulatory agencies globally.

Official documents mandate prominent warnings, similar in severity to a 'Box Warning,' specifically regarding the potential for severe liver toxicity and the non-negotiable limitation on the treatment duration.

How should Nidolon be stored and disposed of?

How to Store and Dispose of Nidolon?

The storage and disposal of Nidolon (Nimesulide) must strictly follow official regulatory requirements to ensure product stability and safety. The medicine is required to be stored at a temperature not exceeding 25°C and must be kept in the original, tightly closed package.

Mandatory storage constraints include keeping the product away from sunlight and moisture and ensuring that it is not frozen. To prevent accidental ingestion, an official requirement is to keep out of reach of children and to store locked up.

Disposal protocols mandate that unused or expired Nidolon must be disposed of via an approved waste disposal plant, such as a drug take-back program. It is strictly prohibited to release the product into the environment, including disposal in household drains or sewer systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nidolon found in:

A-Z Index: